Because approximately half of all mild-moderately-severe asthma is persistently
non-eosinophilic, it is important to determine prospectively if patients who are persistently
non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to
patients who are not persistently non-eosinophilic.